Psychedelic-Assisted Therapy

Psychedelic-Assisted Therapy is a clinical or therapeutic model in which a psychedelic session is paired with preparation and follow-up support. Aliases include Psychedelic therapy.

The phrase should not be used for any unsupervised psychedelic use. In research settings, psychedelic-assisted therapy involves screening, trained support, structured dosing sessions, safety procedures, and integration. The therapy frame is part of the intervention, not a marketing label pasted on afterward.

Experience terms are easiest to misuse because they sound personal and universal at the same time. A word can describe a common pattern without predicting what any one person will feel. Set, setting, dose, sleep, medications, trauma history, and legal context can all change the practical meaning of the same term.

Trials have studied psilocybin-assisted therapy for treatment-resistant depression, major depression, cancer-related distress, and substance-use conditions. Results can be encouraging, but responsible coverage says what the trial reported and who was enrolled.

When this term appears elsewhere on the site, read it as a precision tool rather than a slogan. It helps separate chemistry from culture, research findings from personal reports, and legal status from practical risk. That distinction is especially important for U.S. readers because a term can mean one thing in a peer-reviewed trial, another in an Oregon service-center rule, and something narrower in a city decriminalization ordinance. Clear vocabulary keeps the conversation useful without turning it into advice, and it gives readers a shared baseline before they move into longer guides or state pages.

This term does not mean psilocybin is FDA-approved for general therapy as of this review date. Related terms on MicroDose IQ include integration, breakthrough-therapy-designation, treatment-resistant-depression.